1 active not recruiting, 1 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Familial hyperchylomicronemia syndrome: new trials by email Literature Review of Familial hyperchylomicronemia syndrome trials Research Report on Familial hyperchylomicronemia syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects RN0361 - Hypertriglyceridemia, Familial Chylomicronemia Syndrome | Phase 1 / Phase 2 | Active not recruiting | Ikaria Bioscience Pty Ltd | 108 | 2024-09-30 | 2025-12-30 |
| Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) AKCEA-ANGPTL3-LRx - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 2 | Completed | Akcea Therapeutics | 3 | 2017-12-21 | 2021-01-07 |
| Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia SLx-4090 placebo, Orlistat Placebo, Orlistat - Type 1 Hyperlipoproteinemia | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 5 | 2015-11-01 | 2021-08-19 |
Hypertriglyceridemia (2) · Dyslipidemias (1) · Genetic Diseases, Inborn (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type I (1) · Hyperlipoproteinemias (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1)
Nutritional and Metabolic Diseases (3) · Dyslipidemias (2) · Hyperlipidemias (2) · Lipid Metabolism Disorders (2) · Metabolic Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
6-(4'-trifluoromethyl-6-methoxybiphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl ester (1) · IONIS-ANGPTL3-LRx (1) · Orlistat (1) · vupanorsen (1)
Akcea Therapeutics (1) · Ikaria Bioscience Pty Ltd (1) · University of Texas Southwestern Medical Center (1)
United States (2) · Australia (1) · Canada (1)